Comparison of the effect of normal flushing of heparinized saline with subcutaneous injection of enoxaparin with a prophylactic dose in preventing central venous catheter thrombosis

Phase 3

• Conditions: Vein thrombosis.; Portal vein thrombosis

• Registration Number: IRCT20230428058015N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

All patients with central venous catheter admitted to the intensive care unit
None of the bleeding risk factors
Informed consent of the patient's parent or guardian to participate in the study
Age one month to 18 years

Exclusion Criteria

Risk factors of central venous catheter thrombosis
Anti-coagulant or anti-platelet medication use in the past 5 days
Major surgery in the last 24 hours
Glomerular filtration rate less than 30
Thrombocytopenia (platelets less than 50 thousand)
Kidney, heart and liver disorders
Uncontrolled blood pressure
Lumbar puncture in the last 24 hours

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Thrombosis. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: ultrasound.;Sepsis. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Patient symptoms based on systemic inflammatory response syndrome.;Heart rate. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Arterial pulse taking.;Body Tempretute. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: Thermometer.;Respiration rate. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: observation.;Hemoglobin. Timepoint: At the beginning of the study, 4 and 30 days after the intervention. Method of measurement: ELISA Kit.